Dror Bashan is a experienced Chief Executive Officer with over 20 years of international
experience in the pharmaceutical and biotechnology sectors. Dror has made transformative
contributions to companies under his leadership, driving a business turnaround, fostering
innovation, and enhancing shareholder value. He is currently President, CEO, and Director
of Protalix BioTherapeutics, Inc., a NYSE listed biotherapeutics company, focused on
development, manufacturing and commercialization of rare disease drugs.
At Protalix, Dror has established a strategic framework focussing on drug development and
regulatory approvals in both the U.S. and European Union. Under his leadership, the
company underwent a significant business turnaround, enhanced its product pipeline, and
pursued productive new business development opportunities. He has led key financial
transactions, including private investment in public equity (PIPE), secondary offerings, and
convertible note exchanges. Dror oversees a team of more than 200 employeesdriving a
culture of excellence and innovation.
Prior to Protalix, Dror held various executive roles at Teva Pharmaceutical Industries Ltd.,
one of the world’s leading generic and specialty pharmaceutical companies. As Senior Vice
President of Corporate Business Development, he led multi-billion-dollar strategic alliances
and acquisitions, shaping Teva’s global portfolio across generics, over-the-counter products,
and specialty medicine. During his tenure as Vice President for APAC, he tripled the region’s
revenues and significantly increased profitability, introducing innovative products and
expanding Teva’s footprint in critical markets like South KoreaDror’s earlier roles at Teva
reflect his cross-functional expertise, encompassing sales and marketing, financial strategy,
and operational leadership.
Dror began his career as a Senior Analyst at Bank Leumi le-Israel, one of Israel’s premier
financial institutions. His early exposure to business, finance and strategic analysis has
underpinned his success in the pharmaceutical sector.
Dror holds an MBA in Finance and Strategic Marketing from Tel Aviv University’s School of
Business.. He also earned a BA in Economics and Management from Tel Aviv University. A
multilingual leader, he is fluent in Hebrew and English.
Dror’s leadership philosophy centers on balancing bold innovation with sound governance.
His proven ability to align organizational goals with stakeholder expectations, while
navigating the complexities of the global healthcare industry, sets him apart as a
transformative force in the biopharma sector.
Character
He is a resilient and visionary leader, driven by a passion for fostering innovation and
delivering measurable outcomes while maintaining a strong commitment to ethical
governance and stakeholder value.
Knowledge
With a comprehensive understanding of the pharmaceutical and biotechnology industries,
Dror possesses deep expertise in global business operations, strategic alliances, and
regulatory landscapes across multiple regions.
Strategic
Dror excels in formulating and executing transformative strategies that enhance
organizational performance, drive business turnarounds, and position companies for long-
term success in highly competitive markets.
Communication
An articulate and persuasive communicator, Dror effectively engages with diverse
stakeholders, from employees to board members and investors, fostering collaboration and
alignment toward shared goals.
